Stockscreener 앱 받기
4.93
1.20%
-0.06
시간 외 거래:
4.85
-0.08
-1.62%
전일 마감가:
$4.99
열려 있는:
$4.96
하루 거래량:
4,543
Relative Volume:
0.44
시가총액:
$14.79M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-8.87%
1개월 성능:
+1.34%
6개월 성능:
-69.24%
1년 성능:
+0.00%
1일 변동 폭
$4.82
$5.1299
1주일 범위
$4.82
$5.96
52주 변동 폭
$4.44
$18.22
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
TRAW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TRAW | 4.93 | 14.79M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances - MSN
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger - TipRanks
Traws Pharma Reports Promising Antiviral Drug Progress - TipRanks
Traws Pharma earnings missed by $8.56, revenue topped estimates - Investing.com Canada
Traws Pharma Inc (TRAW) Quarterly 10-Q Report - Quartz
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - The Manila Times
Traws Pharma Reports Promising Phase 1 Data Despite Widening Q3 Losses | TRAW Stock News - StockTitan
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Marketscreener.com
Traws Pharma regains Nasdaq compliance with bid price - Investing.com India
Traws Pharma regains Nasdaq compliance with bid price By Investing.com - Investing.com UK
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment - StockTitan
Traws Pharma Inc (TRAW) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ... - Yahoo Finance
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MyChesCo
Onconova Therapeutics stock hits 52-week low at $4.87 - Investing.com India
Traws Pharma reports positive Phase 1 flu drug results - Investing.com
Traws Pharma reports positive Phase 1 flu drug results By Investing.com - Investing.com Canada
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewswire
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - Marketscreener.com
Onconova Therapeutics stock hits 52-week low at $4.87 By Investing.com - Investing.com Australia
Traws Pharma announces results from its early stage trial for its COVID candidate - MSN
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate - MSN
Traws Pharma reports promising Phase 1 trial for COVID drug - Investing.com
Traws Pharma announces topline Phase 1 results for ratutrelvir - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor - GlobeNewswire
Traws Pharma faces Nasdaq delisting over bid price issue By Investing.com - Investing.com Canada
Traws Pharma faces Nasdaq delisting over bid price issue - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 By Investing.com - Investing.com South Africa
Financial Metrics Check: Traws Pharma Inc. (TRAW)’s Ratios for Trailing Twelve Months - The Dwinnex
Traws Pharma Welcomes Luba Greenwood Amid Strategic Board Changes - MyChesCo
Traws Pharma, Inc. Announces Board Changes - Marketscreener.com
Traws Pharma appoints new director, bids farewell to Marino - Investing.com
Was anything positive for Traws Pharma Inc. (TRAW) stock last session? - US Post News
Traws Pharma Appoints Luba Greenwood to Board of Directors - citybiz
Traws Pharma appoints Luba Greenwood to board of directors - TipRanks
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - GlobeNewswire
Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting - MSN
Closing Figures Unveiled: Traws Pharma Inc. (TRAW) Drop -10.26, Closes at 0.31 - The Dwinnex
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Onconova Therapeutics stock hits 52-week low at $0.32 - Investing.com
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
Traws Pharma announces results of 2024 Special Meeting of Stockholders - TipRanks
Traws Pharma Inc (TRAW) 재무 분석
Traws Pharma Inc (TRAW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):